Tranexamic acid disappoints as prophylaxis in haematologic cancers: ASH

Tranexamic acid offered no benefit over placebo as bleeding prophylaxis in patients with haematologic malignancies undergoing therapies that can induce thrombocytopenia, according to a new study presented at the American Society of Hematology (ASH 2020) Annual Meeting (ASH 2020). “All haemostasis is complex, but bleeding associated with the treatment of haematologic malignancy is perhaps more ...